- Home
- GOSS vs SRG Comparison
GOSS vs SRG Comparison
Compare GOSS & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- SRG
- Stock Information
- Founded
- GOSS 2015
- SRG 2014
- Country
- GOSS United States
- SRG United States
- Employees
- GOSS N/A
- SRG N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- SRG Real Estate Investment Trusts
- Sector
- GOSS Health Care
- SRG Real Estate
- Exchange
- GOSS Nasdaq
- SRG Nasdaq
- Market Cap
- GOSS 262.5M
- SRG 163.3M
- IPO Year
- GOSS 2019
- SRG 2015
- Fundamental
- Price
- GOSS $1.21
- SRG $3.03
- Analyst Decision
- GOSS Strong Buy
- SRG
- Analyst Count
- GOSS 3
- SRG 0
- Target Price
- GOSS $7.33
- SRG N/A
- AVG Volume (30 Days)
- GOSS 2.6M
- SRG 100.5K
- Earning Date
- GOSS 08-11-2025
- SRG 08-13-2025
- Dividend Yield
- GOSS N/A
- SRG N/A
- EPS Growth
- GOSS N/A
- SRG N/A
- EPS
- GOSS N/A
- SRG N/A
- Revenue
- GOSS $124,590,000.00
- SRG N/A
- Revenue This Year
- GOSS N/A
- SRG N/A
- Revenue Next Year
- GOSS $91.14
- SRG N/A
- P/E Ratio
- GOSS N/A
- SRG N/A
- Revenue Growth
- GOSS N/A
- SRG N/A
- 52 Week Low
- GOSS $0.66
- SRG $2.43
- 52 Week High
- GOSS $1.55
- SRG $5.52
- Technical
- Relative Strength Index (RSI)
- GOSS 46.78
- SRG 55.43
- Support Level
- GOSS $1.20
- SRG $2.94
- Resistance Level
- GOSS $1.33
- SRG $3.18
- Average True Range (ATR)
- GOSS 0.10
- SRG 0.11
- MACD
- GOSS -0.02
- SRG 0.01
- Stochastic Oscillator
- GOSS 6.12
- SRG 57.73
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.